Immupharma (IMM)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

 2.38p
   
  • Change Today:
      0.000p
  • 52 Week High: 3.35
  • 52 Week Low: 0.85
  • Currency: UK Pounds
  • Shares Issued: 416.44m
  • Volume: 247,690
  • Market Cap: £9.91m
  • RiskGrade: 328

Growth Ratings

EPS Growth shows the relative growth of a company's earnings over the last year.

The rise in total monies receivable for goods / services sold before expenses.

1yr EPS Growth Not Available
1yr Revenue Growth Not Available

Income Ratings

The percentage of the share price that a company pays out as dividends over a year.

The percentage change from the previous year in the dividend paid on each share.

Dividend Yield Not Available
1yr DPS Growth Not Available

Valuation Ratings

The share price as a ratio of revenue per share.

The share price as a ratio of net asset value.

Price Sales Ratio Not Available
Price Book Ratio
91.78% below the market average91.78% below the market average91.78% below the market average91.78% below the market average91.78% below the market average
63.64% below the sector average63.64% below the sector average63.64% below the sector average63.64% below the sector average63.64% below the sector average

Performance Ratings

In percentage total change in share price over 30 days.

In percentage total change in share price over 3 months.

Price Chg 30d
3.67% below the market average3.67% below the market average3.67% below the market average3.67% below the market average3.67% below the market average
13.21% above the sector average13.21% above the sector average13.21% above the sector average13.21% above the sector average13.21% above the sector average
Price Chg 3m
82.68% above the market average82.68% above the market average82.68% above the market average82.68% above the market average82.68% above the market average
66.04% above the sector average66.04% above the sector average66.04% above the sector average66.04% above the sector average66.04% above the sector average

Technical Ratings

The Relative Strength Index measures a share price relative to itself and its recent history.

Momentum is an oscillator that measures the rate of price change.

RSI
44.57% above the market average44.57% above the market average44.57% above the market average44.57% above the market average44.57% above the market average
34.69% above the sector average34.69% above the sector average34.69% above the sector average34.69% above the sector average34.69% above the sector average
Momentum 20
10.73% above the market average10.73% above the market average10.73% above the market average10.73% above the market average10.73% above the market average
14.29% above the sector average14.29% above the sector average14.29% above the sector average14.29% above the sector average14.29% above the sector average

Management Ratings

Operating Margin is profit as a percentage of sales.

Return on capital employed measures the return from invested and borrowed capital.

Operating Margin Not Available
ROCE Not Available

Profitability Ratings

Earnings per share, the company's profitability expressed on a per share basis.

Analysts' estimates of future EPS for the next 2 years.

EPS
45.87% below the market average45.87% below the market average45.87% below the market average45.87% below the market average45.87% below the market average
16.00% above the sector average16.00% above the sector average16.00% above the sector average16.00% above the sector average16.00% above the sector average
Forecast EPS Not Available

Profit/Loss Ratings

Monies produced from sales of goods and services after trade discounts, VAT, etc.

Operating Profit is the profit after deducting operating costs from gross profits.

Turnover Not Available
Operating Profit Loss
60.98% below the market average60.98% below the market average60.98% below the market average60.98% below the market average60.98% below the market average
4.00% above the sector average4.00% above the sector average4.00% above the sector average4.00% above the sector average4.00% above the sector average

Balance Sheet Ratings

The difference between current assets and current liabilities.

A current asset representing the company's financial liquidity.

Assets
80.17% below the market average80.17% below the market average80.17% below the market average80.17% below the market average80.17% below the market average
79.17% below the sector average79.17% below the sector average79.17% below the sector average79.17% below the sector average79.17% below the sector average
Cash
84.93% below the market average84.93% below the market average84.93% below the market average84.93% below the market average84.93% below the market average
84% below the sector average84% below the sector average84% below the sector average84% below the sector average84% below the sector average

Director Deal Ratings

The cumulative amount of stocks sold by company directors over 1 year

The cumulative amount of stocks bought by company directors over 1 year

Sells 1y Not Available
Buys 1y Not Available

Broker Ratings

The percentage of stockbrokers that rate the company as a Buy

The percentage of stockbrokers that rate the company as a Hold

Brokers Percent Buy Not Available
Brokers Percent Neutral Not Available

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

Immupharma Market Data

Currency UK Pounds
Share Price 2.38p
Change Today 0.000p
% Change 0.00 %
52 Week High 3.35
52 Week Low 0.85
Volume 247,690
Shares Issued 416.44m
Market Cap £9.91m
RiskGrade 328

Immupharma Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
72.71% below the market average72.71% below the market average72.71% below the market average72.71% below the market average72.71% below the market average
33.33% below the sector average33.33% below the sector average33.33% below the sector average33.33% below the sector average33.33% below the sector average
Price Trend
23.23% below the market average23.23% below the market average23.23% below the market average23.23% below the market average23.23% below the market average
16.98% above the sector average16.98% above the sector average16.98% above the sector average16.98% above the sector average16.98% above the sector average
Income Not Available
Growth Not Available

Immupharma Dividends

No dividends found

Trades for 18-Jun-2024

Time Volume / Share Price
14:28 80,000 @ 2.25p
14:27 63,587 @ 2.34p
13:52 43 @ 2.35p
13:49 100,000 @ 2.29p
08:54 4,000 @ 2.27p

Immupharma Key Personnel

CEO Timothy Paul McCarthy

Top of Page